Aurobindo Pharma growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+6.1%+9.4%+16.7%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+4.0%+12.7%+57.1%
+2.7%+14.2%+74.7%
+0.6%+9.9%+64.4%
+0.9%+10.4%+64.6%
+17.5%+10.5%+13.0%
+16.0%+9.4%+11.2%
+40.8%+61.2%+2.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AUROPHARMA₹1,659.90

Aurobindo Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹96,407 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+16.7+9.4+6.1—
EBITDA Growth—+57.1+12.7+4.0—
EBIT Growth—+74.7+14.2+2.7—
Net Income Growth—+64.4+9.9+0.6—
EPS Growth—+64.6+10.4+0.9—
Total Assets Growth—+13.0+10.5+17.5—
Total Equity Growth—+11.2+9.4+16.0—
Cash from Operations Growth—+2.0+61.2+40.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.